3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Prostatic Neoplasms
5
Urinary Bladder Neoplasms
2
Pancreatic Neoplasms
2
Breast Neoplasms
2
Wilms Tumor
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Brain Neoplasms
1
Interventions
Temozolomide
10
Cyclophosphamide
10
Vincristine
9
Etoposide
6
Doxorubicin
6
Irinotecan
5
palbociclib
4
cabozantinib
4
Topotecan
4
Melphalan
4
Magnetic Resonance Spectroscopy
4
X-Rays
3
Sirolimus
3
Phantoms, Imaging
3
Ifosfamide
3
Gemcitabine
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
olaparib
2
ivosidenib
2
irinotecan sucrosofate
2
ganitumab
2
cixutumumab
2
Vemurafenib
2
Trabectedin
2
Tacrolimus
2
Specimen Handling
2
Peripheral Blood Stem Cell Transplantation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Sarcoma, Ewing
×
Genistein
×
Clear all
NCT02624388
2024-05-06
UVA-Gen001
University of Virginia
Phase 2
Terminated
4 enrolled
16 charts